Select Media Coverage

May 12, 2023

Fierce Biotech: Chutes & Ladders - Former Astellas development head jumps to new Frontier

May 12, 2023

Endpoints News: Astellas president jumps to a new Frontier

May 4, 2023

Fierce Biotech: Next round of KRAS drugs stretch for their 4-minute mile in the footsteps of Amgen and Mirati

February 8, 2023

San Francisco Business Times: Why 2023 is shaping up as a critical year for drug makers

July 20, 2021

The Boston Globe: South San Francisco biotech to set up lab in Boston

July 19, 2021

San Francisco Business Times: With focus on the 'undruggable,' Peninsula biotech raises $88.5M from IPO-minded investors

July 19, 2021

Endpoint News: Months after Amgen's landmark KRAS approval, Chris Varma bags a crossover round for next-gen candidate

December 3, 2020

Fierce Biotech: AbbVie Pays Frontier $55M to Pursue Hard-to-Drug Targets

December 3, 2020

BioSpace: Frontier and AbbVie Team Up Against Elusive Protein Targets

December 2, 2020

BioWorld: In Rugged E3 Space, AbbVie Delivers Frontier Justice – the Good Kind – via $1B-Plus Deal

December 2, 2020

Endpoints News: AbbVie Eyes Cancer, Immunology in Latest Protein Degradation Pact, Handing Frontier Medicines $55M Upfront

November 11, 2019

C&EN: C&EN Names Frontier 2019 10 Start-Ups to Watch

September 23, 2019

FierceBiotech: FierceBiotech Names Frontier Medicines One of Its “Fierce 15” Biotech Companies of 2019

June 26, 2019

BioCentury: Frontier Aims for Previously Unreachable 'Hot Spot' Targets with $67M Series A

June 26, 2019

WSJ Venture Capital: Biotech Entrepreneur Chris Varma Scores $67 Million for Frontier Medicines

June 26, 2019

BioWorld: Frontier Medicines Launches with a $67M Series A Round